In this episode Dennis Velasco speaks with Marilyn Huestis from the University of Maryland School of Medicine about novel psychoactive substances (e.g., modafinil, psilocybin, lysergic acid diethylamide, and 3,4-methylenedioxymethamphetamine) and how they simultaneously offer new pharmacotherapies and pose serious health problems. You can read more in the February issue of CPT focused on Designer Drugs.
Listen and subscribe for free on iTunes and Google Play
/
RSS Feed
